154 related articles for article (PubMed ID: 38154068)
1. Pediatric transplant-associated thrombotic microangiopathy health care utilization and implications of eculizumab therapy.
Schoettler ML; Lehmann L; Kao PC; Chen N; Jodele S; Chonat S; Williams KM; London WB; Duncan C; Dandoy C
Blood Adv; 2024 Mar; 8(5):1220-1233. PubMed ID: 38154068
[TBL] [Abstract][Full Text] [Related]
2. Pulmonary Manifestations and Vascular Changes in Pediatric Transplantation-Associated Thrombotic Microangiopathy.
Schoettler ML; Saldana BD; Berkenkamp L; Chonat S; Watkins B; Rotz SJ; Simons D; Graf E; Rossi C; Cheng J; Hammers YA; Rytting H; Williams KM
Transplant Cell Ther; 2023 Jan; 29(1):45.e1-45.e8. PubMed ID: 36202334
[TBL] [Abstract][Full Text] [Related]
3. Thrombotic Microangiopathy Following Pediatric Autologous Hematopoietic Cell Transplantation: A Report of Significant End-Organ Dysfunction in Eculizumab-Treated Survivors.
Schoettler M; Lehmann L; Li A; Ma C; Duncan C
Biol Blood Marrow Transplant; 2019 May; 25(5):e163-e168. PubMed ID: 30639820
[TBL] [Abstract][Full Text] [Related]
4. Use of Eculizumab in Thrombotic Microangiopathy Associated with Hematopoietic Stem Cell Transplantation.
Demircioglu S; Dogan A; Demir C
J Coll Physicians Surg Pak; 2021 Nov; 31(11):1359-1361. PubMed ID: 34689499
[TBL] [Abstract][Full Text] [Related]
5. D-dimer and sinusoidal obstructive syndrome-novel poor prognostic features of thrombotic microangiopathy in children after hematopoietic cellular therapy in a single institution prospective cohort study.
Schoettler ML; French K; Harris A; Bryson E; Deeb L; Hudson Z; Obordo J; Chandrakasan S; Parikh S; Watkins B; Stenger E; Qayed M; Chonat S; Westbrook A; Switchenko J; Williams KM
Am J Hematol; 2024 Mar; 99(3):370-379. PubMed ID: 38164997
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for transplant-associated thrombotic microangiopathy and mortality in a pediatric cohort.
Schoettler M; Lehmann LE; Margossian S; Lee M; Kean LS; Kao PC; Ma C; Duncan CN
Blood Adv; 2020 Jun; 4(11):2536-2547. PubMed ID: 32516415
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Eculizumab in the Treatment of Transplant-Associated Thrombotic Microangiopathy: A Systematic Review and Meta-Analysis.
Zhang R; Zhou M; Qi J; Miao W; Zhang Z; Wu D; Han Y
Front Immunol; 2020; 11():564647. PubMed ID: 33552043
[TBL] [Abstract][Full Text] [Related]
8. Harmonizing Definitions for Diagnostic Criteria and Prognostic Assessment of Transplantation-Associated Thrombotic Microangiopathy: A Report on Behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research.
Schoettler ML; Carreras E; Cho B; Dandoy CE; Ho VT; Jodele S; Moissev I; Sanchez-Ortega I; Srivastava A; Atsuta Y; Carpenter P; Koreth J; Kroger N; Ljungman P; Page K; Popat U; Shaw BE; Sureda A; Soiffer R; Vasu S
Transplant Cell Ther; 2023 Mar; 29(3):151-163. PubMed ID: 36442770
[TBL] [Abstract][Full Text] [Related]
9. Use of Eculizumab in Patients With Allogeneic Stem Cell Transplant-Associated Thrombotic Microangiopathy: A Study From the SFGM-TC.
de Fontbrune FS; Galambrun C; Sirvent A; Huynh A; Faguer S; Nguyen S; Bay JO; Neven B; Moussi J; Simon L; Xhaard A; Resche-Riggon M; O'Meara A; Fremeaux-Bacchi V; Veyradier A; Socié G; Coppo P; de Latour RP
Transplantation; 2015 Sep; 99(9):1953-9. PubMed ID: 25651309
[TBL] [Abstract][Full Text] [Related]
10. Transplant-associated thrombotic microangiopathy: Incidence, prognostic factors, morbidity, and mortality in allogeneic hematopoietic cell transplantation.
Gavriilaki E; Sakellari I; Batsis I; Mallouri D; Bousiou Z; Vardi A; Yannaki E; Constantinou V; Tsompanakou A; Vadikoliou C; Kaloyannidis P; Bamihas G; Anagnostopoulos A
Clin Transplant; 2018 Sep; 32(9):e13371. PubMed ID: 30080283
[TBL] [Abstract][Full Text] [Related]
11. Compassionate Use Narsoplimab for Severe Refractory Transplantation-Associated Thrombotic Microangiopathy in Children.
Schoettler ML; Patel S; Bryson E; Deeb L; Watkins B; Qayed M; Chandrakasan S; Fitch T; Silvis K; Jones J; Chonat S; Williams KM
Transplant Cell Ther; 2024 Mar; 30(3):336.e1-336.e8. PubMed ID: 38145741
[TBL] [Abstract][Full Text] [Related]
12. Intestinal thrombotic microangiopathy: a distinct entity in the spectrum of graft-versus-host disease.
Gavriilaki E; Sakellari I; Karafoulidou I; Pasteli N; Batsis I; Mallouri D; Lazaridou A; Iskas M; Vardi A; Papalexandri A; Tsompanakou A; Papaemmanouil S; Ilias A; Anagnostopoulos A
Int J Hematol; 2019 Nov; 110(5):529-532. PubMed ID: 31586304
[TBL] [Abstract][Full Text] [Related]
13. Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab.
Jodele S; Dandoy CE; Lane A; Laskin BL; Teusink-Cross A; Myers KC; Wallace G; Nelson A; Bleesing J; Chima RS; Hirsch R; Ryan TD; Benoit S; Mizuno K; Warren M; Davies SM
Blood; 2020 Mar; 135(13):1049-1057. PubMed ID: 31932840
[TBL] [Abstract][Full Text] [Related]
14. Use of Eculizumab in Pediatric Patients with High-Risk Transplantation-Associated Thrombotic Microangiopathy: Outcomes and Risk Factors Associated with Response and Survival. A Retrospective Study on Behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC).
Benítez Carabante MI; Bueno D; Alonso García L; López Torija I; Marsal J; Fernandez Navarro JM; Uria Oficialdegui ML; Panesso M; Molina B; Beléndez Bieler C; Palomo P; Pérez Martínez A; Diaz-de-Heredia C
Transplant Cell Ther; 2024 Mar; ():. PubMed ID: 38521410
[TBL] [Abstract][Full Text] [Related]
15. Incidence and Role of Recipient-Specific Antibodies in Allogeneic Hematopoietic Cell Transplantation from Mismatched Related Donors.
Sadowska-Klasa A; Dukat-Mazurek A; Zielińska H; Dębska-Zielkowska J; Piekarska A; Moszkowska G; Mensah-Glanowska P; Zaucha JM
Transplant Cell Ther; 2024 Jan; 30(1):99.e1-99.e10. PubMed ID: 37875214
[TBL] [Abstract][Full Text] [Related]
16. Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation.
Jodele S; Fukuda T; Mizuno K; Vinks AA; Laskin BL; Goebel J; Dixon BP; Chima RS; Hirsch R; Teusink A; Lazear D; Lane A; Myers KC; Dandoy CE; Davies SM
Biol Blood Marrow Transplant; 2016 Feb; 22(2):307-315. PubMed ID: 26456258
[TBL] [Abstract][Full Text] [Related]
17. Predictors of Transplant-Associated Thrombotic Microangiopathy in Patients With Overlap or Chronic Graft-vs-Host-Disease.
Gavriilaki E; Sakellari I; Chatzikonstantinou T; Bousiou Z; Mallouri D; Masmanidou M; Vardi A; Koravou EE; Kika F; Touloumenidou T; Papalexandri A; Yannaki E; Batsis I; Anagnostopoulos A
Transplant Proc; 2021 Sep; 53(7):2261-2266. PubMed ID: 34417030
[TBL] [Abstract][Full Text] [Related]
18. Terminal Complement Blockade after Hematopoietic Stem Cell Transplantation Is Safe without Meningococcal Vaccination.
Jodele S; Dandoy CE; Danziger-Isakov L; Myers KC; El-Bietar J; Nelson A; Wallace G; Teusink-Cross A; Davies SM
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1337-1340. PubMed ID: 27060440
[TBL] [Abstract][Full Text] [Related]
19. Eculizumab for transplant-associated thrombotic microangiopathy in adult allogeneic stem cell transplant recipients.
Rudoni J; Jan A; Hosing C; Aung F; Yeh J
Eur J Haematol; 2018 Sep; 101(3):389-398. PubMed ID: 29920784
[TBL] [Abstract][Full Text] [Related]
20. High mortality in hematopoietic stem cell transplant-associated thrombotic microangiopathy with and without concomitant acute graft-versus-host disease.
Kraft S; Bollinger N; Bodenmann B; Heim D; Bucher C; Lengerke C; Kleber M; Tsakiris DA; Passweg J; Tzankov A; Medinger M
Bone Marrow Transplant; 2019 Apr; 54(4):540-548. PubMed ID: 30108323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
